We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
Cap. Flow
+$233M
Cap. Flow %
5.17%
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$94.6M
2
AZN icon
AstraZeneca
AZN
+$82.2M
3
BAX icon
Baxter International
BAX
+$68.1M
4
CRBU icon
Caribou Biosciences
CRBU
+$60.5M
5
STVN icon
Stevanato
STVN
+$59.9M

Top Sells

Rank Stock Value
1
MRVI icon
Maravai LifeSciences
MRVI
+$124M
2
MDT icon
Medtronic
MDT
+$66.4M
3
BIIB icon
Biogen
BIIB
+$63.7M
4
NEO icon
NeoGenomics
NEO
+$61.7M
5
LLY icon
Eli Lilly
LLY
+$58.1M

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
2 Miscellaneous 13.11%
3 Technology 0.99%
4 Financials 0.64%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$380M 8.41%
+3,021,000
New +$389M
XLRN
2
CALL
DELISTED
Acceleron Pharma
XLRN
$211M 4.68%
+1,228,100
New +$161M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$188M 4.16%
1,062,400
+309,400
+41% +$49.8M
ARVN icon
4
Arvinas
ARVN
$600M
$184M 4.07%
2,234,700
+380,700
+21% +$33.6M
ABBV icon
5
AbbVie
ABBV
$451B
$174M 3.86%
1,613,200
+128,800
+9% +$14.7M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$137B
$168M 3.72%
926,400
-23,600
-2% -$4.61M
ZNTL icon
7
Zentalis Pharmaceuticals
ZNTL
$360M
$166M 3.68%
2,493,800
+333,800
+15% +$19.3M
AVTR icon
8
Avantor
AVTR
$9.86B
$133M 2.94%
3,247,700
+67,700
+2% +$2.65M
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$130M 2.88%
934,200
+51,700
+6% +$6.46M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.74B
$92.2M 2.04%
4,823,400
+208,400
+5% +$3.47M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$81.8B
$92.2M 2.04%
+152,300
New +$94.6M
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$91.2M 2.02%
537,000
-103,000
-16% -$16M
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$90.5M 2%
826,000
+258,000
+45% +$26.8M
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$85.5M 1.9%
832,000
+268,800
+48% +$25M
AZN icon
15
AstraZeneca
AZN
$252B
$84.8M 1.88%
+706,000
New +$82.2M
NBIX icon
16
Neurocrine Biosciences
NBIX
$15.7B
$81.4M 1.8%
848,900
+167,900
+25% +$15.9M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$31.7B
$80.6M 1.79%
427,000
+232,000
+119% +$43.5M
LLY icon
18
Eli Lilly
LLY
$1.05T
$76.2M 1.69%
330,000
-235,500
-42% -$58.1M
NUVB icon
19
Nuvation Bio
NUVB
$2.34B
$72.2M 1.6%
7,263,488
+297,112
+4% +$2.69M
NTRA icon
20
Natera
NTRA
$47B
$71.2M 1.58%
638,700
+202,700
+46% +$23.2M
HOLX
21
DELISTED
Hologic
HOLX
$69.8M 1.55%
945,400
-263,400
-22% -$19.8M
BAX icon
22
Baxter International
BAX
$13.5B
$69.3M 1.54%
+862,000
New +$68.1M
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$67.8M 1.5%
1,139,000
+196,000
+21% +$11.6M
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$66.6M 1.48%
4,100,000
+2,699,990
+193% +$29.4M
UTHR icon
25
United Therapeutics
UTHR
$22.1B
$64.8M 1.44%
351,000
+114,600
+48% +$22.6M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q3 2021 Portfolio in Review

As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $233M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.

  • Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
  • Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
  • Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
  • Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
  • Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
  • Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.